Cargando…

Evaluation of telavancin dose capping in a large community hospital

BACKGROUND: Telavancin is a bactericidal lipoglycopeptide treat susceptible Gram-positive pathogens including Methicillin-resistant Staphylococcus aureus. Pharmacokinetic studies have shown that obese patients have increased exposure to telavancin compared with non-obese patients. Dose capping of 75...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hassoun, Ali, Edwards, Jonathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631713/ http://dx.doi.org/10.1093/ofid/ofx163.656

Ejemplares similares

2364. Evaluation of Renal Function Changes in Patients With Prolonged Telavancin Therapy (>21 Days): Results From the Telavancin Observational Use Registry (TOUR™)
por: Hassoun, Ali, et al.
Publicado: (2018)

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Bressler, Adam M., et al.
Publicado: (2019)

Utilization of the T2 Candida Panel for Rapid Candida Species Detection in a Large Community Hospital
por: Hassoun, Ali, et al.
Publicado: (2017)

Clinical and Economic Evaluation of commercialized Fecal Microbiota Transplant (cFMT) for Patients with Recurrent Clostridium difficile Infection (CDI) in a Large Community Hospital
por: Hassoun, Ali, et al.
Publicado: (2017)

Multidisciplinary Approach to Improve Utilization and Cost Savings of Multiplex Polymerase chain reaction (PCR) Respiratory Pathogen Testing in a Large Community Hospital
por: Hassoun, Ali, et al.
Publicado: (2017)

Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles, et al.
Publicado: (2017)

256. Optimizing the Clinical Utilization of T2 Rapid Candida Panel at a Large Community Hospital
por: Thottacherry, Elizabeth, et al.
Publicado: (2019)

Update on the emerging role of telavancin in hospital-acquired infections
por: Nnedu, Obinna N, et al.
Publicado: (2015)

Safety and Efficacy of Telavancin at an Outpatient Parenteral Antibiotic Therapy (OPAT) Unit in New York City
por: Rodriguez, George D, et al.
Publicado: (2017)

1122. Evaluation of Fecal Microbiota Transplant (FMT) in Elderly Patients With recurrent Clostridium difficile Infection (CDI)
por: Hassoun, Ali, et al.
Publicado: (2018)

Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)

1323. Efficacy and Safety of Telavancin Compared to Vancomycin for Cystic Fibrosis Pulmonary Exacerbation in Adults
por: Shorman, Mahmoud, et al.
Publicado: (2021)

Chemical Stability of Telavancin in Elastomeric Pumps()
por: Sand, Patrick, et al.
Publicado: (2015)

2587. Evaluating Seasonality & Demographic Risk Factors of Hospital Encounters in Patients with Community Acquired Pneumonia (CAP)
por: Lildar, Taikchan, et al.
Publicado: (2023)

2404. Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement
por: Bishop, Aaron, et al.
Publicado: (2018)

528. Hospital Course of Patients Receiving Bamalanivimab: A Real World Analysis
por: Belk, Madeline, et al.
Publicado: (2021)

291 Efficacy and safety of telavancin in the treatment ofram-positive bloodstream infections in cancer patients
por: Chaftari, Anne-Marie, et al.
Publicado: (2014)

Efficacy of telavancin for treatment of surgical site infections
por: Wilson, SE, et al.
Publicado: (2008)

Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Reilly, Joseph, et al.
Publicado: (2020)

1555. Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin–Tazobactam and Vancomycin Compared with Those on Piperacillin–Tazobactam and Telavancin
por: Reilly, Joseph, et al.
Publicado: (2019)

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
por: Rubinstein, Ethan, et al.
Publicado: (2011)

Pharmacokinetics and safety of a single dose of telavancin in pediatric subjects 2–17 years of age
por: Bradley, John S., et al.
Publicado: (2023)

Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles R., et al.
Publicado: (2021)

Role of telavancin in treatment of skin and skin structure infections
por: Bonkowski, Joseph, et al.
Publicado: (2010)

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
por: al Jalali, Valentin, et al.
Publicado: (2018)

2369. Clinical Experience With Telavancin for Treatment of Patients With Monomicrobial S. aureus Infections (Vancomycin MIC ≥1 μg/mL) From TOUR™
por: Jacobs, Micah, et al.
Publicado: (2018)

2213. Etiology of Community-Acquired Pneumonia (CAP) in Hospitalized Native American Adults
por: Hammitt, Laura, et al.
Publicado: (2019)

Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2009)

Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia
por: Rubinstein, Ethan, et al.
Publicado: (2014)

1002. Epidemiology of Pneumococcal Bacteremia in a Large Tertiary Center
por: Asis, Aristotle, et al.
Publicado: (2018)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

2425. Correlating Use of High-Risk Antimicrobials and the Incidence of Hospital-Onset Clostridium difficile Infection: Targeting Prescribing Trends for Antimicrobial Stewardship
por: Thottacherry, Elizabeth, et al.
Publicado: (2019)

1415. Implementation and Validation of a Vancomycin AUC/MIC Calculator and Dosing Protocol at a Large Community Hospital
por: Seddon, Megan, et al.
Publicado: (2018)

780 Clinical Characteristics And Outcomes among Children with Neurological Disorders Hospitalized with Community-acquired Pneumonia (CAP) in the Etiology of Pneumonia in the Community (EPIC) Study
por: Millman, Alexander J., et al.
Publicado: (2014)

Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections
por: Jafari Saraf, Lida, et al.
Publicado: (2011)

Efficacy and Safety of Telavancin in Clinical Trials: A Systematic Review and Meta-Analysis
por: Polyzos, Konstantinos A., et al.
Publicado: (2012)

1201. Putting a CAP on Discharge Antimicrobial Therapy: Evaluation of a Systematic Transitions of Care Process for Patients with Community Acquired Pneumonia (CAP) and Chronic Obstructive Pulmonary Disease (COPD)
por: Belza, Ana Christine, et al.
Publicado: (2023)

Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
por: Hooper, Candace Y, et al.
Publicado: (2012)

Post-reconstitution Stability of Telavancin with Commonly Used Diluents and Intravenous Infusion Solutions
por: Gu, Zhengtian, et al.
Publicado: (2015)

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)
por: Dunbar, Lala M, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_0jiffg1sl2ih42prni6hvhlfc1